- Beretta leaves Maryland over gun laws, heads for Tennessee
- Neal Boortz defends Hillary Clinton for representing child rapist
- House task force to recommend National Guard on border, faster deportations
- Top federal judge uses pizza to explain complex Obamacare situation
- Obama, Biden overhaul job training programs
- Drought-plagued Californians turn to paint to keep lawns green
- ISIL now forcing Iraqi shopkeepers to veil mannequins in Mosul
- 11 parents of Nigeria’s abducted girls die
- Genetic mapping triggers new hope on schizophrenia
- Turkish P.M. Erdogan won’t speak to Obama, but he’ll take calls from Biden
NIH plans center to spur creation of new drugs
Question of the Day
WASHINGTON (AP) - The nation’s premier research agency plans to open a new center this fall to spur creation of medications because of concern that exciting discoveries aren’t being turned into treatments fast enough.
The plan is on track despite the increasingly likely prospect of budget cuts for the venerable National Institutes of Health, agency chief Dr. Francis Collins said Wednesday.
The idea: Do more of the risky early-stage research into promising compounds that drug companies are increasingly reluctant to invest in. It’s a period called “the valley of death” because so many of those early experiments fail.
“The valley of death needs to become a valley that leads to life,” Collins told reporters. “The time is right even in a difficult budget environment, maybe especially in a difficult budget environment.”
That kind of drug-related research isn’t new for the NIH. The cancer drug taxol and AIDS drug AZT, for example, originated from NIH work, Collins noted, and agency researchers have 550 projects under way devoted to various medications, vaccines or medical devices. He cited recent research that found 20 percent of innovative new medications that hit the market in recent years originated from NIH-funded research _ as the drug industry’s own research productivity has declined.
The National Center for Advancing Translational Sciences would bring much of NIH’s current drug development research _ about $700 million worth, from a $30 billion budget _ under one roof so scientists could better collaborate, Collins said. It also will explore new techniques to predict, for instance, which experimental medications will be safe enough to test in people faster than is done today.
The plan has drawn some objections by researchers and others concerned about the dismantling of another NIH center at the same time, projects that Collins said will be taken over by other parts of the agency.
But some high-profile patient advocacy groups are praising the change. Fewer than 200 of 7,000 rare diseases have an available therapy, said James O’Leary of the Genetic Alliance.
“That’s just too slow,” he said. “This translational medicine focus is critical to the mission of NIH.”
The Bethesda, Md.-based NIH plans to open the center Oct. 1.
TWT Video Picks
The president could pay the full price for ignoring Congress
- David Perdue defeats Jack Kingston in Georgia Republican Senate primary runoff
- IRS seeks help destroying another 3,200 computer hard drives
- 'Straight White Guy Festival' supposedly set for Ohio park
- D.C. appeals panel deals big blow to Obamacare subsidies
- Beretta moving to Tennessee over Maryland gun laws
- BERMAN & MADYOON: An Iranian-Turkish reset
- MAY: Barbarians at Jordan's gate
- EDITORIAL: Obamacare in intensive care
- Pentagon team dispatched to Ukraine amid crisis with Russia
- Hamas terrorists wear Israeli army uniforms to ambush soldiers in Gaza
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq